Market overview
The global cell therapy market is worth USD 9.4 bn in 2026 and is forecast to reach USD 58.0 bn by 2036, growing at a 20.0% CAGR. United States is the largest country market and CAR-T cells is the largest by cell type segment.
| Scope | Commercial cell therapies in which living cells are given to patients, including CAR-T therapies, tumour-infiltrating lymphocytes, mesenchymal stem cell products and cord blood-based treatments. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 7.5 bn |
| Value 2026 | USD 9.4 bn |
| Value 2036 | USD 58.0 bn |
| CAGR 2026-2036 | 20.0% |
| Volume 2026 | 27.9 thousand patients |
| Volume 2036 | 201 thousand patients |
| Average price 2026 | USD 335,800 per patient |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Cell Therapy market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 9.4 bn |
| 2027 | USD 11.2 bn |
| 2028 | USD 13.5 bn |
| 2029 | USD 16.2 bn |
| 2030 | USD 19.4 bn |
| 2031 | USD 23.3 bn |
| 2032 | USD 28.0 bn |
| 2033 | USD 33.6 bn |
| 2034 | USD 40.3 bn |
| 2035 | USD 48.4 bn |
| 2036 | USD 58.0 bn |
Cell Therapy market segmentation
By cell type
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| CAR-T cells | 72.0% | 72.1% | USD 6.8 bn | 20.0% |
| Other immune cells | 8.0% | 12.0% | USD 750 mn | 25.0% |
| Stem cell therapies | 15.0% | 11.7% | USD 1.4 bn | 17.0% |
| Others | 5.0% | 4.2% | USD 469 mn | 18.0% |
By indication
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Blood cancers | 76.0% | 58.3% | USD 7.1 bn | 16.9% |
| Solid tumours | 6.0% | 27.7% | USD 562 mn | 39.8% |
| Autoimmune | 3.0% | 6.6% | USD 281 mn | 29.8% |
| Other | 15.0% | 7.4% | USD 1.4 bn | 11.9% |
By therapy type
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Autologous | 56.0% | 52.0% | USD 5.2 bn | 19.1% |
| Allogeneic | 34.0% | 36.0% | USD 3.2 bn | 20.7% |
| Off-the-shelf iPSC derived | 10.0% | 12.0% | USD 938 mn | 22.2% |
By phase of care
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Preclinical and early clinical | 14.0% | 12.0% | USD 1.3 bn | 18.2% |
| Late clinical | 22.0% | 18.0% | USD 2.1 bn | 17.6% |
| Commercial supply | 64.0% | 70.0% | USD 6.0 bn | 21.1% |
By product source
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| CAR-T | 50.0% | 48.0% | USD 4.7 bn | 19.5% |
| Stem cell therapy | 24.0% | 22.0% | USD 2.2 bn | 19.0% |
| TCR and TIL | 10.0% | 12.0% | USD 938 mn | 22.2% |
| NK and others | 16.0% | 18.0% | USD 1.5 bn | 21.4% |
Top 25 countries for cell therapy by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 97.0% of 2026 revenue and the 25 countries below together hold 99.3%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 5.6 bn | 60.0% | USD 34.4 bn | 19.9% |
| 2 | Germany | USD 562 mn | 6.0% | USD 3.2 bn | 19.0% |
| 3 | China | USD 562 mn | 6.0% | USD 5.6 bn | 25.9% |
| 4 | France | USD 469 mn | 5.0% | USD 2.6 bn | 18.7% |
| 5 | Japan | USD 469 mn | 5.0% | USD 2.8 bn | 19.8% |
| 6 | United Kingdom | USD 375 mn | 4.0% | USD 2.1 bn | 18.7% |
| 7 | Italy | USD 375 mn | 4.0% | USD 1.9 bn | 17.7% |
| 8 | Spain | USD 281 mn | 3.0% | USD 1.5 bn | 17.8% |
| 9 | Canada | USD 188 mn | 2.0% | USD 1.0 bn | 18.7% |
| 10 | Netherlands | USD 188 mn | 2.0% | USD 1.0 bn | 18.7% |
| 11 | Switzerland | USD 43 mn | 0.5% | USD 261 mn | 19.7% |
| 12 | Israel | USD 33 mn | 0.3% | USD 197 mn | 19.6% |
| 13 | Australia | USD 25 mn | 0.3% | USD 151 mn | 19.6% |
| 14 | South Korea | USD 24 mn | 0.3% | USD 168 mn | 21.3% |
| 15 | Belgium | USD 19 mn | 0.2% | USD 116 mn | 20.0% |
| 16 | Sweden | USD 14 mn | 0.1% | USD 87 mn | 20.0% |
| 17 | Austria | USD 12 mn | 0.1% | USD 70 mn | 19.0% |
| 18 | Brazil | USD 9.4 mn | 0.1% | USD 70 mn | 22.2% |
| 19 | India | USD 9.4 mn | 0.1% | USD 64 mn | 21.1% |
| 20 | Singapore | USD 7.5 mn | 0.08% | USD 52 mn | 21.4% |
| 21 | Poland | USD 6.6 mn | 0.07% | USD 46 mn | 21.6% |
| 22 | Denmark | USD 5.6 mn | 0.06% | USD 35 mn | 20.0% |
| 23 | Taiwan | USD 4.7 mn | 0.05% | USD 29 mn | 20.0% |
| 24 | Saudi Arabia | USD 2.8 mn | 0.03% | USD 23 mn | 23.5% |
| 25 | Ireland | USD 2.8 mn | 0.03% | USD 17 mn | 20.0% |
| Rest of world | USD 62 mn | 0.7% | USD 412 mn | 20.9% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Gilead Sciences (Kite)
- Bristol Myers Squibb
- Novartis
- Johnson and Johnson
- Legend Biotech
Group 2: Regional and specialist players
- Iovance Biotherapeutics
- Vertex Pharmaceuticals
- Mesoblast
- Vericel
- Atara Biotherapeutics
- Adaptimmune
- JCR Pharmaceuticals
Group 3: Emerging and niche players
- JW Therapeutics
- CARsgen Therapeutics
- Autolus Therapeutics
- IASO Bio
- Juventas Cell Therapy
- Medipost
- Pharmicell
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the cell therapy market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 20.0% is calculated from the resulting values.
The market is divided by cell type, by indication, by therapy type, by phase of care, by product source. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the cell therapy market?
The global cell therapy market is estimated at USD 7.5 bn in 2025 and USD 9.4 bn in 2026.
How fast will the cell therapy market grow?
It is forecast to reach USD 58.0 bn by 2036, a compound annual growth rate of 20.0% from 2026, an increase of USD 48.7 bn.
Which country is the largest market for cell therapy?
United States is the largest market by revenue at USD 5.6 bn in 2026, 60.0% of the global total. The three largest countries together hold 72.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 25.9% a year from 2026 to 2036.
Which cell therapy segment is largest?
In the by cell type split, CAR-T cells is the largest segment with 72.0% of 2026 revenue.
Who are the leading cell therapy companies?
Global leaders include Gilead Sciences (Kite), Bristol Myers Squibb, Novartis, Johnson and Johnson.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Protein PurificationUSD 9.3 bn · 9.0% CAGR
- Softgel CapsuleUSD 9.6 bn · 6.6% CAGR
- VialUSD 9.7 bn · 7.5% CAGR
- Pharmaceutical LabelingUSD 9.0 bn · 5.8% CAGR
- Lateral Flow AssayUSD 10.0 bn · 5.0% CAGR
- Pharmaceutical ExcipientsUSD 10.1 bn · 6.5% CAGR
- Biomarker DiscoveryUSD 8.7 bn · 11.5% CAGR
- FermentationUSD 10.3 bn · 8.5% CAGR